Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
P/E ratio for Arcellx, Inc. (ACLX)
P/E ratio as of 2023: -37.73
According to Arcellx, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -37.73. At the end of 2022 the company had a P/E ratio of -7.34.
P/E ratio history for Arcellx, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -37.73 |
| 2022 | -7.34 |
| 2021 | -9.39 |
| 2020 | -17.56 |
| 2019 | -32.51 |
| 2018 | -0.33 |